OncoMatch/Clinical Trials/NCT03861676
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Is NCT03861676 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies (18F)DCFPyL for prostate cancer.
Treatment: (18F)DCFPyL — The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease. In the PI's clinical trial, the uninvolved regions (as defined by combined PET-MR-biopsy data) will not be targeted and receive only fall-off dose, which we have shown to be associated with reductions in toxicity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: gleason 6gleason 7 (gleason)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pelvic radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SKCCC at Johns Hopkins · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify